Opendoor Technologies Inc vs Revvity Inc — how do they compare? Opendoor Technologies Inc trades at $2.21 (market cap $2.22B), while Revvity Inc trades at $154.78 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.6× Opendoor Technologies Inc's market cap, and Revvity Inc pays a 0.18% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and Revvity Inc for 12 Days on average.
| OPEN | RVTY | |
|---|---|---|
Market Cap | $2.22B | $16.98B |
Volume | 28,705,892 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $157.36 |
52-Week Low | $2.27 | $82.26 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $3.29B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies (OPEN) trades at $2.215, down 2.42% on the day, reflecting ongoing challenges in the iBuying sector. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentals reveal significant losses with a -46.74% net income margin and -$1.3B net loss in 2025. Recent news highlights mortgage expansion efforts and housing market sensitivity to interest rate fluctuations, with the company aiming for adjusted net income breakeven at a $9B revenue run rate.
Despite trading near analyst consensus price target of $4.92 (122% upside), OPEN faces substantial execution risks amid persistent losses and high debt levels. The bullish case relies on successful mortgage expansion and housing market recovery, but current financial metrics and technical indicators suggest continued volatility. Investors should weigh the significant discount to analyst targets against the company's challenging path to profitability.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →